Events

Radium Capital, Australia’s leader in R&D finance, has announced plans to lend $400 million to Australian innovators over the next 12 months. 

Australian antiviral drug development company, Island Pharmaceuticals (ASX:ILA) has provided top-line results from its Phase 2a/b PROTECT Trial of ISLA101 in a human challenge model of dengue virus infection.

Cochlear has launched its new smart cochlear implant system, Cochlear Nucleus Nexa System, which is designed and manufactured in Australia.

Cyclopharm (ASX:CYC) has announced that the United States Patent and Trademark Office (USPTO) has granted the maximum allowable patent term extension of five years covering the TECHNEGAS Kit (technetium Tc-99m labelled carbon) to 2031.

AusBiotech 2025, Australia’s premier life sciences and investment conference, has officially opened early bird registrations, and the countdown is on.

In its once-in-a-decade report ‘Our Future World’, Australia’s national science agency identified seven global megatrends that will shape our lives in the coming decades. Among them is the escalating health imperative.

New data presented today at the Public Health Association of Australia's Communicable Diseases and Immunisation Conference have shown that cell-based influenza vaccines were nearly 20 per cent more effective at preventing test-confirmed infections compared to traditional standard-dose egg-based vaccines.

Imricor Medical Systems (ASX:IMR) has received CE Mark certification under the European Union’s Medical Device Regulation for its NorthStar Mapping System.

Clinical dermatology company, Botanix Pharmaceuticals (ASX:BOT), has entered into documentation with Kreos Capital VII and its related entities for a loan facility of up to the euro equivalent of US$30 million.

Argenica Therapeutics (ASX:AGN) states that it has received correspondence from the US FDA, indicating that a clinical hold has been placed on the company's Investigational New Drug Application.

Syntara (ASX:SNT) has announced that its lead candidate, SNT5505, has been granted Fast Track Designation by the US FDA for the treatment of myelofibrosis in patients with an inadequate response to JAK inhibitor therapy.

EMVision Medical Devices (ASX:EMV) has announced the appointment of Ramsay CEO Carmel Monaghan as an independent non-executive director.